Do Wall Street Analysts Like Agilent Technologies Stock?

Santa Clara, California-based Agilent Technologies, Inc. (A) provides application-focused solutions to the beingness sciences, diagnostics, and applied chemic markets worldwide. With a marketplace headdress of $41.6 billion, the institution operates done Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab segments.

The healthcare elephantine has somewhat underperformed the broader marketplace implicit the past year. Agilent’s banal prices have gained 9.3% connected a YTD ground and 12.8% implicit the past 52 weeks, compared to the S&P 500 Index’s ($SPX) 14.5% gains successful 2025 and 13.2% returns implicit the past year.

• Nvidia's Earnings Report Will Be Out connected Wednesday, Nov. 19 - How to Play NVDA Stock

• NVDA Earnings, FOMC and Other Key Things to Watch this Week

• The Market Just Pulled Back. Here Is How To Protect Gains And Reset Risk

• Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you successful the know. Sign up now!

Narrowing the focus, the banal has outpaced the sector-focused Healthcare Select Sector SPDR Fund’s (XLV) 10.4% gains connected a YTD ground and 5.1% uptick implicit the past 52 weeks.

Agilent Technologies’ banal prices gained 5.3% successful a azygous trading league pursuing the merchandise of its better-than-expected Q3 results connected Aug. 27. The institution reported a coagulated 10.1% year-over-year surge successful nett revenues to $1.7 billion, exceeding the Street’s expectations by 4.6%. Meanwhile, its adjusted nett income inched up by a humble 1.3% year-over-year to $390 million, but its adjusted EPS of $1.37 surpassed the consensus estimates by 74 bps.

For the afloat fiscal 2025, ended successful October, analysts expect Agilent to present an adjusted EPS of $5.58, up 5.5% year-over-year. Further, the institution has a coagulated net astonishment history. It has surpassed the Street’s bottom-line projections successful each of the past 4 quarters.

Among the 16 analysts covering the Agilent stock, the statement standing is simply a “Moderate Buy.” That’s based connected 9 “Strong Buys” and 7 “Holds.”

This configuration is notably much optimistic than 2 months ago, erstwhile 7 analysts gave “Strong Buy” recommendations.

On Oct. 14, TD Cowen expert Dan Brennan reiterated a “Buy” standing connected Agilent and raised the terms people from $150 to $162.

Agilent’s mean terms people of $151.92 represents a humble 3.5% premium to existent terms levels. Meanwhile, the street-high people of $170 suggests a notable 15.8% upside potential.

On the day of publication, Aditya Sarawgi did not person (either straight oregon indirectly) positions successful immoderate of the securities mentioned successful this article. All accusation and information successful this nonfiction is solely for informational purposes. This nonfiction was originally published connected Barchart.com